Also known as: Kerendia
Finerenone is a non-steroidal mineralocorticoid receptor antagonist marketed as Kerendia. It is used for chronic kidney disease associated with type 2 diabetes and for heart failure with left ventricular ejection fraction of 40% or higher. In the U.S., it was first approved on July 9, 2021.
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594145 |
Precision T1D Platform - New Therapies for Cardio-Renal Complications |
NOT_YET_RECRUITING | PHASE2 |
| NCT07585526 |
Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease. |
NOT_YET_RECRUITING | NA |
| NCT07575672 |
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure |
NOT_YET_RECRUITING | PHASE3 |
| NCT07547878 |
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07537088 |
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease |
NOT_YET_RECRUITING | PHASE4 |
| NCT07523867 |
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT07442448 |
Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07351864 |
Finerenone Plus SGLT2 Inhibitors in Heart Failure |
NOT_YET_RECRUITING | PHASE4 |
| NCT07326631 |
Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure |
NOT_YET_RECRUITING | NA |
| NCT07270367 |
Finerenone and Cardiac Remodeling |
NOT_YET_RECRUITING | PHASE3 |
